Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
| Autor: | Noha Elsadany, Naglaa A El-Gendy, Fathiya El-Raey, Sherif A Nassib |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Medicine (General)
medicine.medical_specialty medicine.medical_treatment Gastroenterology End stage renal disease chemistry.chemical_compound R5-920 Internal medicine Ombitasvir/paritaprevir/ritonavir medicine hepatitis c end stage renal disease hemodialysis business.industry Ribavirin virus diseases Hepatitis C medicine.disease Ombitasvir chemistry Paritaprevir Ritonavir direct acting antiviral drugs viral infection Hemodialysis business medicine.drug |
| Zdroj: | International Journal of Medical Arts, Vol 2, Iss 1, Pp 313-319 (2020) |
| ISSN: | 2682-3780 |
| DOI: | 10.21608/ijma.2020.21730.1068 |
| Popis: | Background: Hepatitis C virus (HCV) infection is associated with more significant morbidity and mortality among dialysis patients than in healthy populations. The fixed-dose tablet (ombitasvir/ paritaprevir/ritonavir) in combination with ribavirin was effective and generally well tolerated in treatment of chronic HCV infected patients with end stage renal disease (ESRD) on hemodialysis. However, limited published data are known about the usefulness of this regimen for treatment of HCV patients with ESRD on hemodialysis. Aim of the work: The aim of this study was to evaluate the safety and efficacy of treatment regimen of ombitasvir (OBV) 25 mg /paritaprevir (PTV) 150 mg /ritonavir (RTV) 100 mg plus generic ribavirin (RBV) 200 mg in Egyptian HCV-infected naive patients with ESRD on regular hemodialysis. Patients and methods: A prospective cohort study involved 40 chronic HCV on regular hemodialysis patients, who were eligible for treatment with combined oral antiviral therapy. Results: The results showed that thirty-five patients [35/40(87.5%)] completed 12 weeks of HCV therapy; they had a virological response at end of therapy and sustained virological response. Anemia was the main observed side effect which lead to discontinuation of the treatment in five patients (12.2%). As these patients were not responding to anemia correction measures (blood transfusion, erythropoietin-stimulating agents, and modification of RBV dose). Conclusion: OBV/PTV/RTV plus Ribavirin can be used in treatment of chronic HCV patients with ESRD on regular hemodialysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|